First analysis of TCAR in standard surgical risk

Large-scale analysis of TCAR in the treatment of patients at standard surgical risk presented at the 2021 annual meeting of the Society for Vascular Surgery

SUNNYVALE, Calif., Aug. 18, 2021 (GLOBE NEWSWIRE) – Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, is pleased to highlight the positive results of An independent review of standard surgical risk patients undergoing carotid endarterectomy (CE) and transcarotid artery revascularization (TCAR) for atherosclerotic carotid disease. The analysis, presented today at the 2021 Vascular Annual Meeting of the Society for Vascular Surgery (VAM) in San Diego, Calif., Is the first-ever presentation of TCAR results in patients at standard surgical risk.

More than 20,000 patients at standard surgical risk were included in the analysis (15,198 CEA and 5,066 TCAR) of the VQI CEA and carotid stent (CAS) registers over 4 years (August 2016 to September 2020). Results for symptomatic and asymptomatic standard surgical risk patients undergoing CEA and TCAR for atherosclerotic carotid disease showed that TCAR had stroke and death outcomes statistically equivalent to ECA, while showing a reduction of nine times cranial nerve damage (CNI) (2.7% vs. 0.3%, p = <0.001).

“The promise of safely preventing stroke while providing the benefits of a less invasive approach is of critical importance as we consider a larger patient population. This first-ever large-scale standard surgical risk analysis demonstrates that TCAR is delivering on this promise, ”said Erica Rogers, President and CEO of Silk Road Medical.

“These results reinforce the efficacy of TCAR as an important treatment option for patients with carotid artery disease and standard surgical risk factors,” said Dr. Marc L. Schermerhorn, Division Head of vascular and endovascular surgery at Beth Israel Deaconess Medical Center. “TCAR again shows a risk equivalent to ACE of perioperative stroke, death or MI and ipsilateral stroke at one year in patients undergoing carotid revascularization with improved secondary outcomes such as heart injury. cranial nerve. “

the Annual Meeting of the Society for Vascular Vascular Surgery is frequented by vascular surgeons and vascular health professionals. To view the summary, visit: Expansion of Transcarotid Artery Revascularization in Patients at Standard Surgical Risk for the Treatment of Carotid Artery Stenosis

About TCAR with the ENROUTE Transcarotid Neuroprotection and Stent Graft System
TCAR (TransCarotid Artery Revascularization) is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages of the carotid artery at risk of causing stroke. The ENROUTE Transcarotid Stent Graft is intended for use in patients at high risk for complications from CEA, in conjunction with the ENROUTE Transcarotid Neuroprotection System (NPS) during the TCAR procedure. ENROUTE Transcarotid NPS is a first-class device used to directly access the common carotid artery and initiate a temporary high-flow blood flow reversal to protect the brain from stroke during placement and removal. implantation of the ENROUTE Transcarotide endoprosthesis.

About Silk Road Medical
Silk Road Medical, Inc. (NASDAQ: SILK) is a Sunnyvale, California-based medical device company focused on reducing the risk of stroke and its devastating impact. The company has launched a new approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR). TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat carotid artery blockages at risk of causing stroke. For more information on how Silk Road Medical delivers better patient outcomes through more informed clinical thinking, visit www.silkroadmed.com and connect on Twitter, LinkedIn and Facebook

Investors:
Lynn Lewis or Marissa Bych
Gilmartin Group
[email protected]

Media:
Michel Fanucchi
Medical Silk Road
[email protected]